A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 May 2018
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms MAIA
- Sponsors Genmab; Janssen Research & Development; Janssen-Cilag
- 03 May 2018 Planned End Date changed from 22 Nov 2024 to 22 Nov 2022.
- 15 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Jun 2017 Planned End Date changed from 22 Nov 2022 to 22 Nov 2024.